Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | GRM8 | O00222 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 5/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.30 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.30 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13361955 | 0.81 | GRM8 (0.31) | GRM8CYP1A2GRM7 | |
| SCHEMBL3325859 | 0.79 | AMY1A (0.32) | GRM8CYP1A2GRM7 | |
| SCHEMBL970413 | 0.69 | CRHR1 (0.36) | — | |
| SCHEMBL30954965 | 0.69 | — | — | |
| SCHEMBL158153 | 0.68 | TAAR1 (0.56) | TAAR1CYP1A2 | |
| SCHEMBL18713980 | 0.65 | TAAR1 (0.48) | TAAR1CYP1A2 | |
| SCHEMBL21000886 | 0.63 | TAAR1 (0.50) | TAAR1CYP1A2 | |
| SCHEMBL30184066 | 0.63 | TAAR1 (0.50) | TAAR1CYP1A2 | |
| SCHEMBL30954923 | 0.62 | PLAU (0.34) | — | |
| SCHEMBL13862076 | 0.62 | TAAR1 (0.48) | TAAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010054260-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120763-A1 | IMIDAZO[5,1-C][1,2,4]BENZOTRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | PDE2A, PDE5A, PDE3A | TAAR1 1107/4885GRM8 3122/4885CYP1A2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.